Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Texas Oncology at Baylor Irving Cancer Center
mi
from
Irving, TX
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Texas Oncology at Baylor Irving Cancer Center
mi
from
Irving, TX
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Yale University
mi
from
New Haven, CT
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Baylor University Medical Center
mi
from
Dallas, TX
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
A Randomized Phase II Study of the Nutritional Supplements Juice Plus + and Juice Plus + Complete in Ovarian Cancer Patients
Status: Enrolling
Updated:  3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Juice Plus+ and Juice Plus+ Complete in Ovarian Cancer
A Randomized Phase II Study of the Nutritional Supplements Juice Plus + and Juice Plus + Complete in Ovarian Cancer Patients
Status: Enrolling
Updated: 3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies
Status: Enrolling
Updated:  3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
A Phase I Study of MLN9708 and Vorinostat to Target Autophagy in Patients With Advanced p53 Mutant Malignancies
Status: Enrolling
Updated: 3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Status: Enrolling
Updated:  3/20/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
A Pilot Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ System
Status: Enrolling
Updated: 3/20/2018
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention
Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention
Status: Enrolling
Updated:  3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention
Changes in Patient Reported Constipation Among Advanced Cancer Patients After Receiving an Educational Intervention
Status: Enrolling
Updated: 3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Occupational Therapy in Palliative Care
Is Inpatient Occupational Therapy Perceived to be Beneficial by the Palliative Patient and Caregiver?
Status: Enrolling
Updated:  3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Occupational Therapy in Palliative Care
Is Inpatient Occupational Therapy Perceived to be Beneficial by the Palliative Patient and Caregiver?
Status: Enrolling
Updated: 3/20/2018
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/20/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/20/2018
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated:  3/20/2018
Oregon Health and Science University
mi
from
Portland, OR
Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
A Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Adenocarcinoma
Status: Enrolling
Updated: 3/20/2018
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
Anabolic Response Cancer
Assessment of Anabolic Responsiveness to Protein Intake in Advanced Cancer
Status: Enrolling
Updated:  3/20/2018
Texas A&M University-CTRAL
mi
from
College Station, TX
Anabolic Response Cancer
Assessment of Anabolic Responsiveness to Protein Intake in Advanced Cancer
Status: Enrolling
Updated: 3/20/2018
Texas A&M University-CTRAL
mi
from
College Station, TX
Click here to add this to my saved trials
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Status: Enrolling
Updated:  3/21/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Status: Enrolling
Updated: 3/21/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Status: Enrolling
Updated:  3/21/2018
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Lapatinib Ditosylate in Treating Patients With Ductal Breast Carcinoma In Situ
Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer
Status: Enrolling
Updated: 3/21/2018
University of Alabama at Birmingham Cancer Center
mi
from
Birmingham, AL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Central Illinois Hematology Oncology Center
mi
from
Springfield, IL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Oncology Care Associates, PLLC
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Virginia Commonwealth University Massey Cancer Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Mercy UC Davis Cancer Center
mi
from
Merced, CA
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Mercy UC Davis Cancer Center
mi
from
Merced, CA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Moffitt Cancer Center
mi
from
Tampa, FL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Emory University Hospital-Winship Cancer Institute
mi
from
Atlanta, GA
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Emory University Hospital-Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
NorthShore University HealthSystem-Evanston Hospital
mi
from
Evanston, IL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Ingalls Memorial Hospital
mi
from
Harvey, IL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Ingalls Memorial Hospital
mi
from
Harvey, IL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Joliet Oncology-Hematology Associates Limited
mi
from
Joliet, IL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Loyola University Medical Center
mi
from
Maywood, IL
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Loyola University Medical Center
mi
from
Maywood, IL
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Fort Wayne Medical Oncology and Hematology Inc-Parkview
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Mercy Hospital Saint Louis
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Montefiore Medical Center-Wakefield Campus
mi
from
Bronx, NY
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Montefiore Medical Center-Wakefield Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Montefiore Medical Center - Moses Campus
mi
from
Bronx, NY
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Mount Sinai Hosp
mi
from
New York, NY
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
University of Pittsburgh Cancer Institute (UPCI)
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Medical University of South Carolina
mi
from
Charleston, SC
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Vanderbilt University/Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
M D Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated:  3/21/2018
London Regional Cancer Program
mi
from
London,
Dasatinib in Treating Patients With Recurrent or Metastatic Malignant Salivary Gland Tumors
Phase II Trial of Dasatinib (BMS 354825) for Recurrent or Metastatic c-KIT Expressing Adenoid Cystic Carcinoma and Non-adenoid Cystic Malignant Salivary Tumors
Status: Enrolling
Updated: 3/21/2018
London Regional Cancer Program
mi
from
London,
Click here to add this to my saved trials
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  3/21/2018
Boulder Community Hospital
mi
from
Boulder, CO
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 3/21/2018
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  3/21/2018
Porter Adventist Hospital
mi
from
Denver, CO
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 3/21/2018
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  3/21/2018
Rose Medical Center
mi
from
Denver, CO
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 3/21/2018
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  3/21/2018
Swedish Medical Center
mi
from
Englewood, CO
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 3/21/2018
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials